Implementation of Histopathology in GI Clinical Trials

Join our expert panel where they will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including Histopathology as a treatment target in IBD: Aspiration or Reality? Measuring histopathology in IBD trials Histopathology as a treatment target in NASH trials Measuring histopathology in NASH trials Followed by a panel discussion including questions from our viewers, led by Dr. Vipul Jairath, Chief Medical Officer, Alimentiv Inc.

Therapeutic Areas
Recent Posts
Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials
Speak to a member of our expert team.
Contact Us